Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Próximos ensaios clínicos
-
Seoul National University HospitalSamil Pharmaceutical Co., Ltd.RecrutamentoSarcopenia | Artroplastia Total do JoelhoCoréia do Sul
-
Stanford UniversityAinda não está recrutandoLeucemia mielóide aguda | Síndromes Mielodisplásicas | Neoplasia MieloproliferativaEstados Unidos
-
Cheng QiRecrutamentoPost-hepatectomy HypoalbuminemiaChina
-
Stanford UniversityAinda não está recrutandoInsuficiência hepáticaEstados Unidos
-
Istanbul Aydın UniversityAinda não está recrutandoDor de pescoço | Síndrome Dolorosa Miofascial | Distúrbios Osteomusculares Relacionados ao TrabalhoTurquia (Türkiye)
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Ainda não está recrutandoCarcinoma endometrial recorrente | Carcinoma Endometrial Avançado | Carcinoma endometrial metastático | Câncer de Endométrio Estágio III | Câncer de Endométrio Estágio IVEstados Unidos
-
University of Colorado, DenverRecrutamentoEscoliose Idiopática do Adolescente (EIA) | Escoliose neuromuscularEstados Unidos
-
University of FloridaAmerican Heart AssociationRecrutamentoInsuficiência Cardíaca com Fração de Ejeção Preservada (ICFFE)Estados Unidos
-
UNC Lineberger Comprehensive Cancer CenterAinda não está recrutandoLeucemia | Leucemia linfoblástica aguda | Linfoma linfoblástico | Leucemia Aguda | Leucemia Linfóide AgudaEstados Unidos
-
Korea University Anam HospitalThe Catholic University of Korea; Keimyung University Dongsan Medical Center; Medical...Ainda não está recrutandoCâncer Urológico | Lesão miocárdica após cirurgia não cardíaca | Principais eventos cardiovasculares adversos (MACE)
-
Montefiore Medical CenterAinda não está recrutandoCesarean Scar Defect (Isthmocele)Estados Unidos
-
SanofiAinda não está recrutando
Clinical Research Jobs
-
Philippines - Manila
-
Taiwan - Taipei
-
United States - Shrewsbury
-
Germany - Munich
-
Germany - Nordrhein-Westfalen - CologneAustria
-
Serbia - Belgrade
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China